1
Clinical Trials associated with Anti-CD19 CAR-T cell therapy(Bioceltech Therapeutics Ltd)Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen receptors (referred to as "CD19-CAR-T cells") in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).
Start Date20 Jul 2018 |
Sponsor / Collaborator- |
100 Clinical Results associated with Anti-CD19 CAR-T cell therapy(Bioceltech Therapeutics Ltd)
100 Translational Medicine associated with Anti-CD19 CAR-T cell therapy(Bioceltech Therapeutics Ltd)
100 Patents (Medical) associated with Anti-CD19 CAR-T cell therapy(Bioceltech Therapeutics Ltd)
100 Deals associated with Anti-CD19 CAR-T cell therapy(Bioceltech Therapeutics Ltd)